In the first episode of our series exploring Corporate Law and AI, our experts, Partner Vik Khurana (Commercial Technology) and Of Counsel Richard Swaine (Corporate & Tax), focused on the current state of AI transactional work and recognising and protecting value.

Find all the episodes as we release them here, and don’t forget to subscribe!

Note: All information was correct at the time of recording. (20.03.25)

Following the CJEU’s landmark decision in the BSH v Electrolux case (C-339/22), patent litigators Andrew Bowler and Gregory Bacon discuss the three questions referred by the Swedish Court of Appeal to the European court.

Explore our more detailed analysis here

Note: All information was correct at the time of recording.

It's hard to believe that six months have passed since we released the 11th edition of our Biotech Review of the Year publication.

Our editors, Greg Bacon, Xisca Borrás, and Will Hewitt, thought now would be a great time to catch up and discuss any developments since the launch.

You can also find written updates on the following articles here:

• Integrating generative AI into the life science ecosystem – five tips for success
• Revision of the EU pharmaceutical law regime – what does it mean for biotech companies?
• The first 12 months of the Unified Patent Court
• The application of G2/21 by the Court of Appeal
• Strategic considerations for partnering with CDMOs for cell and gene therapies
• Biotech settlement agreements – a competition law checklist

In this episode our experts Iain Redford (corporate), Miranda Cass (tax) and Gareth Wadley (employment and global mobility) set out the key considerations and potential pitfalls involved in Acquihire deals - an increasing trend we see from across the Atlantic as strategic buyers and institutions look to acquire the best talent and technology to drive innovation.

Find all the episodes as we release them here, and don’t forget to subscribe!

Note: All information was correct at the time of recording.

In this episode of Tech M&A, our experts, Jamie Drucker and Richard Swaine look at the regulatory challenges facing Adtech companies and consider how commercial and legal diligence - and approach to transaction risk - in Adtech M&A may have to refocus in the light of those challenges. 

Find all the episodes as we release them here, and don’t forget to subscribe!

Note: All information was correct at the time of recording.

In this episode of Tech M&A, our experts, Sophie Rees and Jamie Hatzel discuss some of the recent trends affecting medtech M&A, in particular recent regulatory changes which are affecting the evolution of the sector. They also discuss some of the M&A pitfalls which have arisen out of those trends – and how focussed due diligence can help investors avoid them.

Find all the episodes as we release them here, and don’t forget to subscribe!

Note: All information was correct at the time of recording.

Chris Bates and Jamie Hatzel round out this three-part series with a discussion of the likely impact of the Statutory Disclosure Regime proposals on the medtech sector, and how medtech will have to play catch-up to remain compliant once the Statutory Disclosure Regime comes into force.

 The Statutory Disclosure Regime consultation closes on 16 October 2023. To learn more and submit a response, see the link here.

Note: All information was correct at the time of recording. 

Jamie Hatzel and Vivien Zhu delve into some of the finer details of the Statutory Disclosure Regime proposals, including the scope of the proposed regime and the role that voluntary disclosure schemes could continue to play once the regime comes into force. Vivien also talks through how the Statutory Disclosure Regime should prompt some companies to consider whether their data protection arrangements are sufficient.

 The Statutory Disclosure Regime consultation closes on 16 October 2023. To learn more and submit a response, see the link here.

Note: All information was correct at the time of recording. 

Chris Bates and Vivien Zhu introduce the UK government’s consultation on a statutory regime for disclosure of transfers of value to the healthcare sector by the life sciences industry. Chris talks about the historical context of voluntary schemes for disclosures of transfers of value, while Vivien introduces the data protection implications of such disclosures.

The Statutory Disclosure Regime consultation closes on 16 October 2023. To learn more and submit a response, see the link here.

Note: All information was correct at the time of recording. 

In this episode, experts Chris Devlin and Julia Cockroft explore the impact the National Security and Investment Act 2021 has had on transactions involving companies active in AI. The conversation then moves onto the valuable R&D tax reliefs that might be available to businesses harnessing the power of AI and how those reliefs should be taken into account as part of deal negotiations.

Find all the episodes as we release them here, and don’t forget to subscribe!

Note: All information was correct at the time of recording.